Select filter conditions
Specialty
Select filter conditions
Solutions
Select filter conditions
Procedure
Category
Found 6 Results
Embolization Coils
AZUR™ CX
AZUR™ CX is the first and only peripheral hydrogel coil with cross-sectional coverage and the benefits of patented hydrogel technology.
AZUR™ CX is the first and only peripheral hydrogel coil with cross-sectional coverage and the benefits of patented hydrogel technology.
Embolization Coils
AZUR™ Framing coil
AZUR™ Framing coil is a platinum coil that offers a three-dimensional shape to cover the wall of an aneurysm or the inner lumen of an artery.
AZUR™ Framing coil is a platinum coil that offers a three-dimensional shape to cover the wall of an aneurysm or the inner lumen of an artery.
Embolization Coils
AZUR™ HydroCoil System
AZUR™ combines a platinum coil and a hydrogel polymer that expands in the direction of less resistance to fill space when introduced into the bloodstream.
AZUR™ combines a platinum coil and a hydrogel polymer that expands in the direction of less resistance to fill space when introduced into the bloodstream.
Stents
Ultimaster Nagomi™
Ultimaster™ Nagomi™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.
Ultimaster™ Nagomi™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.
Stents
Ultimaster™
Ultimaster™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.
Ultimaster™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.
Stents
Ultimaster™ Tansei™
Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.
Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System is the most studied reliable Biodegradable Polymer-DES, with over 50,000 patients worldwide.